Case report of relapsing COVID-19 infection in a patient with multiple sclerosis treated with ocrelizumab

Czech version

Authors: J. Pazderková ¹; H. Bartoš ^1,2; P. Dlouhý ¹; M. Vachová ^3,4
Authors‘ workplace: Infekční oddělení, Masarykova nemocnice, Krajská zdravotní a. s., Ústí nad Labem ¹; 3. LF UK, Praha ²; RS centrum, Neurologické oddělení, Nemocnice Teplice, Krajská zdravotní a. s., Teplice ³; 1. LF UK, Praha ⁴
Published in: Cesk Slov Neurol N 2021; 84/117(1): 92-94
Category: Letter to Editor
doi: https://doi.org/10.48095/cccsnn202192

Sources

1. Giovannoni G, Hawkes C, Lechner-Scott J et al. The COVID-19 pandemic and the use of MS disease--modifying therapies. Mult Scler Relat Disord 2020; 39 : 102073. doi: 10.1016/j.msard.2020.102073.

2. Mehta P, McAuley DF, Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033–1034. doi: 10.1016/S0140-6736 (20) 30628-0.

3. Dabiao C, Wenxiong X, Ziying L et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report. Int J Infect Dis 2020; 93 : 297–299. doi: 10.1016/j.ijid.2020.03.003.

4. Syed YY. Ocrelizumab: a review in multiple sclerosis. CNS Drugs 2018; 32 (9): 883–890. doi: 10.1007/s40263-018-0568-7.

5. Novi G, Mikulska M, Briano F et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord 2020; 42 : 102120. doi: 10.1016/j.msard.2020.102120.

6. Louapre C, Collongues N, Stankoff B et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 2020; 77 (9): 1079–1088. doi: 10.1001/jamaneurol.2020.2581.